JP2022540611A5 - - Google Patents
Info
- Publication number
- JP2022540611A5 JP2022540611A5 JP2022501134A JP2022501134A JP2022540611A5 JP 2022540611 A5 JP2022540611 A5 JP 2022540611A5 JP 2022501134 A JP2022501134 A JP 2022501134A JP 2022501134 A JP2022501134 A JP 2022501134A JP 2022540611 A5 JP2022540611 A5 JP 2022540611A5
- Authority
- JP
- Japan
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025061352A JP2025156278A (ja) | 2019-07-11 | 2025-04-02 | Ｄｌｌ３をターゲッティングする抗体とその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962872915P | 2019-07-11 | 2019-07-11 | |
| US62/872,915 | 2019-07-11 | ||
| PCT/US2020/041282 WO2021007371A1 (en) | 2019-07-11 | 2020-07-08 | Dll3-targeting antibodies and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025061352A Division JP2025156278A (ja) | 2019-07-11 | 2025-04-02 | Ｄｌｌ３をターゲッティングする抗体とその使用 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022540611A JP2022540611A (ja) | 2022-09-16 |
| JP2022540611A5 true JP2022540611A5 (https=) | 2023-07-12 |
| JPWO2021007371A5 JPWO2021007371A5 (https=) | 2023-07-12 |
| JP7661299B2 JP7661299B2 (ja) | 2025-04-14 |
Family
ID=74115317
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022501134A Active JP7661299B2 (ja) | 2019-07-11 | 2020-07-08 | Ｄｌｌ３をターゲッティングする抗体とその使用 |
| JP2025061352A Pending JP2025156278A (ja) | 2019-07-11 | 2025-04-02 | Ｄｌｌ３をターゲッティングする抗体とその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025061352A Pending JP2025156278A (ja) | 2019-07-11 | 2025-04-02 | Ｄｌｌ３をターゲッティングする抗体とその使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12441789B2 (https=) |
| EP (1) | EP3997127A4 (https=) |
| JP (2) | JP7661299B2 (https=) |
| KR (1) | KR20220034167A (https=) |
| CN (3) | CN118955717A (https=) |
| AU (1) | AU2020310894A1 (https=) |
| BR (1) | BR112022000216A2 (https=) |
| CA (1) | CA3146566A1 (https=) |
| CO (1) | CO2022001195A2 (https=) |
| IL (1) | IL289585A (https=) |
| MX (1) | MX2022000325A (https=) |
| PH (1) | PH12022550056A1 (https=) |
| WO (1) | WO2021007371A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO2718257T3 (https=) * | 2014-05-30 | 2018-04-14 | ||
| CN118955717A (zh) * | 2019-07-11 | 2024-11-15 | 纪念斯隆凯特琳癌症中心 | Dll3靶向抗体及其用途 |
| CA3204628A1 (en) * | 2021-01-13 | 2022-07-21 | John T. POIRIER | Antibody-pyrrolobenzodiazepine derivative conjugate |
| TW202245844A (zh) * | 2021-01-13 | 2022-12-01 | 紀念斯隆凱特琳癌症中心 | 抗dll3抗體-藥物結合物 |
| CN117529337A (zh) * | 2021-05-08 | 2024-02-06 | 上海齐鲁制药研究中心有限公司 | 针对dll3的结合分子及其应用 |
| JP2024532486A (ja) * | 2021-09-02 | 2024-09-05 | メモリアル スローン ケタリング キャンサー センター | Ｄｌｌ３を標的とする抗原認識受容体及びその使用 |
| WO2023034566A1 (en) * | 2021-09-02 | 2023-03-09 | Memorial Sloan-Kettering Cancer Center | Anti-dll3 antibodies and uses thereof |
| WO2023034557A1 (en) * | 2021-09-02 | 2023-03-09 | Memorial Sloan-Kettering Cancer Center | Radioligand binding to anti-dll3 antibodies for pretargeted pet imaging and therapeutic uses thereof |
| TW202346346A (zh) * | 2021-12-23 | 2023-12-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 抗ｄｌｌ３抗體、其抗體－藥物偶聯物及其醫藥用途 |
| KR20240149438A (ko) | 2022-02-27 | 2024-10-14 | 베링거 인겔하임 인터내셔날 게엠베하 | Cd277 및 종양-항원에 대한 이중특이적 항체 |
| CN116003628A (zh) * | 2022-08-15 | 2023-04-25 | 南京博安生物技术有限公司 | 靶向人dll3抗原的全人源特异性嵌合抗原受体及其应用 |
| WO2025184421A1 (en) * | 2024-02-28 | 2025-09-04 | Juno Therapeutics, Inc. | Chimeric antigen receptors and antibodies specific for delta-like ligand 3 (dll3) and related methods |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005016111A2 (en) | 2003-08-08 | 2005-02-24 | Abgenix, Inc. | Antibodies directed to parathyroid hormone (pth) and uses thereof |
| US7718774B2 (en) * | 2006-11-08 | 2010-05-18 | Macrogenics, Inc. | TES7 and antibodies that bind thereto |
| EP3907242A1 (en) * | 2010-01-29 | 2021-11-10 | Chugai Seiyaku Kabushiki Kaisha | Anti-dll3 antibody |
| WO2012013813A1 (en) | 2010-07-30 | 2012-02-02 | Gianluca Moroncini | Epitopes of the human pdgf receptor able to bind human auto-antibodies, antibodies and uses thereof |
| EP3453723B1 (en) * | 2012-01-31 | 2021-08-11 | Regeneron Pharmaceuticals, Inc. | Anti-asic1 antibodies and uses thereof |
| PE20190658A1 (es) * | 2012-02-24 | 2019-05-08 | Abbvie Stemcentrx Llc | Moduladores y metodos de empleo novedosos |
| PE20161209A1 (es) | 2014-02-21 | 2016-11-10 | Abbvie Stemcentrx Llc | Conjugados de anticuerpos anti-drosophila similar a delta 3 (anti-dll3) y medicamentos para usarse en el tratamiento contra melanoma |
| AR101669A1 (es) | 2014-07-31 | 2017-01-04 | Amgen Res Munich Gmbh | Constructos de anticuerpos para cdh19 y cd3 |
| RS61010B1 (sr) * | 2014-11-20 | 2020-11-30 | Hoffmann La Roche | Bispecifični antigen vezujući molekuli koji aktiviraju t ćelije protiv folr1 i cd3 |
| CN118955717A (zh) * | 2019-07-11 | 2024-11-15 | 纪念斯隆凯特琳癌症中心 | Dll3靶向抗体及其用途 |
-
2020
- 2020-07-08 CN CN202411174926.2A patent/CN118955717A/zh active Pending
- 2020-07-08 PH PH1/2022/550056A patent/PH12022550056A1/en unknown
- 2020-07-08 CN CN202411174923.9A patent/CN119080930A/zh active Pending
- 2020-07-08 BR BR112022000216A patent/BR112022000216A2/pt unknown
- 2020-07-08 JP JP2022501134A patent/JP7661299B2/ja active Active
- 2020-07-08 EP EP20836805.0A patent/EP3997127A4/en active Pending
- 2020-07-08 CN CN202080062231.9A patent/CN114341182B/zh active Active
- 2020-07-08 AU AU2020310894A patent/AU2020310894A1/en active Pending
- 2020-07-08 WO PCT/US2020/041282 patent/WO2021007371A1/en not_active Ceased
- 2020-07-08 MX MX2022000325A patent/MX2022000325A/es unknown
- 2020-07-08 US US17/622,404 patent/US12441789B2/en active Active
- 2020-07-08 CA CA3146566A patent/CA3146566A1/en active Pending
- 2020-07-08 KR KR1020227004114A patent/KR20220034167A/ko active Pending
-
2022
- 2022-01-03 IL IL289585A patent/IL289585A/en unknown
- 2022-02-04 CO CONC2022/0001195A patent/CO2022001195A2/es unknown
-
2025
- 2025-04-02 JP JP2025061352A patent/JP2025156278A/ja active Pending